Baidu
map

NATURE:H +转运是线粒体ADP / ATP载体的整合功能

2019-07-27 海北 MedSci原创

线粒体ADP / ATP载体(AAC)是线粒体内膜的主要转运蛋白。它交换线粒体ATP和细胞溶质ADP,并控制ATP的细胞产生。 此外,研究人员已经提出AAC可以介导线粒体解偶联,但人们难以证明该功能或阐明其机制。

线粒体ADP / ATP载体(AAC)是线粒体内膜的主要转运蛋白。它交换线粒体ATP和细胞溶质ADP,并控制ATP的细胞产生。
此外,研究人员已经提出AAC可以介导线粒体解偶联,但人们难以证明该功能或阐明其机制。
最近,研究人员直接从各种小鼠组织的线粒体内膜记录AAC电流,并确定两种不同的转运模式:ADP / ATP交换和H +转运。 
AAC介导的H +电流需要游离脂肪酸,并且类似于通过棕色脂肪中发现的产热解偶联蛋白1的H +泄漏。
通过AAC的ADP / ATP交换负向调节H +泄漏,但不完全抑制它。
这表明H +泄漏和线粒体解偶联可以通过细胞ATP需求,以及ADP / ATP交换速率动态控制。
通过介导两种不同的转运模式,即ADP / ATP交换和H +泄漏,AAC连接线粒体中的偶联(ATP产生)和非偶联(产热)能量转换。


原始出处:
Bertholet AM et al. H+ transport is an integral function of the mitochondrial ADP/ATP carrier. NATURE 2018, DOI: 10.1038/s41586-019-1400-3

本文系梅斯医学(MedSci)原创编译整理,转载需授权! 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696342, encodeId=44e916963423f, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Tue Nov 05 05:32:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645474, encodeId=4b0416454e451, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 02:32:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883794, encodeId=c5111883e944e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 06 00:32:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461672, encodeId=d54614616e265, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Sun Jul 28 21:32:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370338, encodeId=3b5c3e033839, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 27 08:25:43 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-11-05 yzh409
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696342, encodeId=44e916963423f, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Tue Nov 05 05:32:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645474, encodeId=4b0416454e451, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 02:32:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883794, encodeId=c5111883e944e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 06 00:32:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461672, encodeId=d54614616e265, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Sun Jul 28 21:32:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370338, encodeId=3b5c3e033839, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 27 08:25:43 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2020-05-07 mei539
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696342, encodeId=44e916963423f, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Tue Nov 05 05:32:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645474, encodeId=4b0416454e451, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 02:32:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883794, encodeId=c5111883e944e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 06 00:32:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461672, encodeId=d54614616e265, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Sun Jul 28 21:32:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370338, encodeId=3b5c3e033839, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 27 08:25:43 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-09-06 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696342, encodeId=44e916963423f, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Tue Nov 05 05:32:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645474, encodeId=4b0416454e451, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 02:32:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883794, encodeId=c5111883e944e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 06 00:32:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461672, encodeId=d54614616e265, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Sun Jul 28 21:32:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370338, encodeId=3b5c3e033839, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 27 08:25:43 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-28 listen320
  5. [GetPortalCommentsPageByObjectIdResponse(id=1696342, encodeId=44e916963423f, content=<a href='/topic/show?id=0107934e0a5' target=_blank style='color:#2F92EE;'>#转运#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93470, encryptionId=0107934e0a5, topicName=转运)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=47c429881595, createdName=yzh409, createdTime=Tue Nov 05 05:32:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1645474, encodeId=4b0416454e451, content=<a href='/topic/show?id=db329364360' target=_blank style='color:#2F92EE;'>#载体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93643, encryptionId=db329364360, topicName=载体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58cb23213384, createdName=mei539, createdTime=Thu May 07 02:32:00 CST 2020, time=2020-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883794, encodeId=c5111883e944e, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Sep 06 00:32:00 CST 2019, time=2019-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461672, encodeId=d54614616e265, content=<a href='/topic/show?id=6f3829619b' target=_blank style='color:#2F92EE;'>#ATP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2961, encryptionId=6f3829619b, topicName=ATP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d5806435870, createdName=listen320, createdTime=Sun Jul 28 21:32:00 CST 2019, time=2019-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=370338, encodeId=3b5c3e033839, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 27 08:25:43 CST 2019, time=2019-07-27, status=1, ipAttribution=)]
    2019-07-27 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

相关资讯

潜力巨大:线粒体蛋白酶活性调节剂ONC201和ONC212治疗癌症

Oncoceutics制药公司近日宣布,两篇科学研究论文证明了咪唑啉酮化合物ONC201和ONC212能够直接激活一种称为酪蛋白溶解蛋白酶P(ClpP)的线粒体蛋白酶。

Blood:CLL细胞会损害CD8+ T细胞的线粒体适应性、降低CAR T细胞疗法疗效!

在慢性淋巴细胞白血病(CLL)中,获得性T细胞功能缺陷的机制尚未明确,极大阻碍了T细胞免疫疗法的发展。Jaco A. C. van Bruggen等人既往发现,在受到刺激后,CLL中的CD8+ T细胞表现出激活受损和葡萄糖摄取减少。CLL患者的CD8+ T细胞长期暴露于白血病B细胞的环境下,可能会影响代谢稳态,从而导致受刺激时发生异常的代谢重编程。现Jaco等人再次在CLL中,静止的CD8+ T细

Nat Commun:癌症治疗差异性竟与线粒体数量相关

同一基因组的癌细胞为何对同一疗法产生不同的治疗疗效呢?目前已知很多原因会导致这一现象的产生。最近,来自西奈山和IBM的研究人员通过对TNF相关细胞凋亡诱导配体(TRAIL)的诱导和使用一个新的统计方法,证明可变线粒体丰度与细胞存活和细胞死亡反应相关。

Leber遗传性视神经病变的治疗或许不再是难题:GS010的REVERSE III期试验数据即将公布

GenSight是一家专注于开发视网膜神经退行性疾病和中枢神经系统疾病创新基因疗法的生物制药公司,近日宣布GS010的REVERSE III期临床试验结果将于2019年3月16日至21日在第45届北美神经眼科学会(NANOS)年会上公布。

PNAS:5-羟色胺可以增强神经元动力,帮助抵抗压力

神经元里也有线粒体,线粒体在应激状态下产生能量来执行细胞功能和调节神经元存活。

Eur Respir J:血浆线粒体DNA与肺外结节病相关

由此可见,结节病中细胞外线粒体DNA的富集与肺外疾病和AA血统有关。进一步研究这些临床发现的机制可能会产生新的病理生理学和治疗理论。

Baidu
map
Baidu
map
Baidu
map